Patent ID: 11946927
Assignee: nan
Field: Pharmaceuticals (Chemistry)
Classification: CPC G  A  Y | IPC A  G

Claim 1:
2. The process of claim 1, wherein if the risk value of the selected individual developing IBD is greater than the cut-off value for the prediction logistic regression model used for determining the risk value of an individual developing IBD and/or if the therapy and any modifications in the therapy being administered to the selected individual for reducing the risk value for developing IBD does not reduce the risk value of the selected individual below the cut-off value of the reduction logistic regression model used for determining the risk value of an individual developing IBD, the process includes the steps of:
obtaining a blood sample of the selected individual;
examining the blood sample to obtain a level of each predictive target biomarker listed in a prediction panel of predictive target biomarkers for predicting the risk of an individual developing Crohn's disease and a total level of protein in the blood sample;
using a prediction logistic regression model that uses the predictive target biomarkers listed in the prediction panel of predictive target biomarkers to calculate a risk value of the selected individual developing Crohn's disease;
wherein if the calculated risk value for the selected individual of developing Crohn's disease is greater than a cut-off value for the prediction logistic regression model for predicting the risk of an individual developing Crohn's disease, administering a therapy for treating Crohn's disease;
wherein the therapy for treating Crohn's disease includes administering a medication known for treating Crohn's disease and repeating the process of determining the risk value of the selected individual for developing Crohn's disease, wherein if the risk value increases or remains the same, making modifications to the therapy and repeating the process of determining the risk value for developing Crohn's disease and continue with the therapy or modifying the therapy until the risk value of the selected individual for developing Crohn's disease is below a cut-off value for the prediction logistic regression model;
wherein the list of predictive target biomarkers in the predictive prediction panel of predictive target biomarkers for use in determining the risk of an individual developing Crohn's disease comprises the target biomarkers AutoAb to topisomerase type 1 (SLC70), Angiotensin 1 converting enzyme (AcE), RETN, CRP, GCSF and Antibody TT and identifies the relationships of sICAM1×RETN, GCSF×Antibody TT; and
wherein the prediction logistic regression model for determining the risk value for an individual developing Crohn's disease is Log (p/1ip)=−174.4+171.2×SLC70−4.0×AcE−32.2×RETN+1.1×CRP+15.9×GCSF−57.4×Antibody TT+11.6×(sICAM1×RETN)−2.7×(GCSF×Antibody TT) and the cut-off value is 0.5.